RPTP News Alert Raptor Pharmaceutical (RPTP) 9.34 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Raptor Pharmaceutical (RPTP) 9.34 $RPTP

Commit To Purchase Raptor Pharmaceuticals At $7.50, Earn 33.3% Using Options
at The Street - Wed Dec 24, 11:18AM CST
Investors considering a purchase of Raptor Pharmaceuticals Corp. shares, but tentative about paying the going market price of $9.32/share, might benefit from considering selling puts among the alternative strategies at their disposal.
RPTP: 9.34 (+0.56)

The 2015 Calendar Of NASH Trial Catalysts Series Brings Huge Opportunities For Investors
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 2:29AM CST

RPTP: 9.34 (+0.56), CNAT: 6.84 (+0.17)

Raptor Pharmaceutical Appoints Gregg Lapointe and Georges Gemayel to Board of Directors
GlobeNewswire - Thu Dec 18, 6:30AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced the appointment of Gregg Lapointe and Georges Gemayel, Ph.D. to its Board of Directors, effective January 1, 2015. As previously disclosed, they will be joining Julie Anne Smith, President and CEO-Designate as she succeeds Christopher Starr, Ph.D., as Chief Executive Officer and joins the Board effective January 1, 2015.
RPTP: 9.34 (+0.56)

Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.62 (+0.03), PFNX: 7.33 (-0.05), INO: 9.11 (-0.09), CMRX: 36.80 (+0.70), RPTP: 9.34 (+0.56), IBIO: 0.68 (-0.04), ANAC: 30.58 (+0.16), PFE: 31.42 (-0.03), GNCA: 7.42 (-0.11), GSK: 42.85 (+0.11), AZN: 70.44 (+0.26), NVS: 93.91 (+0.66)

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/48lh7t/non_alcoholic) has announced the addition of the "Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - F. Hoffmann-La Roche - Merck & Co - Novartis - Daewoong Pharmaceutical - Orchid Chemicals & Pharmaceuticals - Phynova Group - Raptor Pharmaceuticals - Phenex Pharmaceuticals - Metabolic Solutions Development - Zafgen - Verva Pharmaceuticals - Galmed International - TCM Biotech International For more information visit http://www.researchandmarkets.com/research/48..._alcoholic
RPTP: 9.34 (+0.56), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)

Raptor Pharmaceutical Corp. Is An Investment With Significant Upside IN 2015
Clinically Sound Investor - at Seeking Alpha - Thu Dec 04, 8:57AM CST

RPTP: 9.34 (+0.56)

Parkinson's Disease - Pipeline Review, H2 2014
M2 - Tue Dec 02, 5:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/7k9xvt/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 169 companies are cited in this text including: - Amicus Therapeutics, Inc. - AstraZeneca PLC - Bial - Portela & Ca, S.A. - Calico LLC - Cardax Pharmaceuticals, Inc. - Edison Pharmaceuticals, Inc. - GlaxoSmithKline plc - GliaCure Inc. - H. Lundbeck A/S - Io Therapeutics, Inc. - Iproteos S.L. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Medeia Therapeutics Ltd. - Motac Neuroscience Ltd - Netherlands Translational Research Center B.V. - nLife Therapeutics, S.L. - Novartis AG - OPKO Health, Inc. - Orion Oyj - Peptron, Inc. - Pfizer Inc. - QR Pharma, Inc. - QRxPharma Limited - Raptor Pharmaceuticals Corp. - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Stelic Institute & Co. - Sumitomo Dainippon Pharma Co., Ltd. For more information visit http://www.researchandmarkets.com/research/7k9xvt/parkinsons
RPTP: 9.34 (+0.56), KNMD: (), OPK: 9.63 (+0.21), PFE: 31.42 (-0.03), AZN: 70.44 (+0.26), GSK: 42.85 (+0.11), FOLD: 7.94 (+0.06), NVS: 93.91 (+0.66)

Raptor Pharmaceutical awards inducement grants to seven new employees under NASDAQ Listing Rule 5635(c) (4)
M2 - Tue Dec 02, 5:32AM CST
Biopharmaceutical company Raptor Pharmaceutical (NasdaqGM:RPTP) said on Monday that its board of directors has announced inducement stock option awards to seven new employees on 25 November 2014.
RPTP: 9.34 (+0.56)

Raptor Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire - Mon Dec 01, 8:09AM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that on November 25, 2014, as a key requirement of the Company's strategy of strengthening its leadership team and employee base, continuing the expansion of its commercial activities into new territories, and increasing the expansion of its product development programs, the board of directors approved inducement stock option awards to new hire employees pursuant to the Raptor Pharmaceutical Corp. 2014 Employment Commencement Stock Incentive Plan. The plan was approved by the board of directors under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company. The grants consisted of stock options to purchase an aggregate of 217,288 shares of the Company's common stock to six new employees and an option to purchase 165,000 shares to David Happel, the Company's new Chief Commercial Officer, each with a per share exercise price of $9.92, the closing price on the trading date immediately prior to the grant date.
RPTP: 9.34 (+0.56)

Insider Trading Alert - RPTP, TEAR And ISRG Traded By Insiders
at The Street - Wed Nov 26, 10:59AM CST
Stocks with insider trader activity include RPTP, TEAR and ISRG
ISRG: 530.94 (+4.78), TEAR: 2.60 (-0.03), RPTP: 9.34 (+0.56)

Raptor Pharmaceutical to Present at the 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 18, 3:10PM CST
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will participate in the following conference:
RPTP: 9.34 (+0.56)

Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 9.34 (+0.56), TEVA: 57.09 (+0.33), ASPX: 49.93 (-0.10), GSK: 42.85 (+0.11), PRAN: 1.74 (-0.02), VRX.TO: 162.98 (-0.62)

Raptor Pharmaceutical's (RPTP) CEO Chris Starr on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:58PM CST

RPTP: 9.34 (+0.56)

Raptor Pharmaceutical tops Street 3Q forecasts
Automated Insights - Thu Nov 06, 5:18PM CST
NOVATO, Calif. (AP) _ Raptor Pharmaceutical Corp. (RPTP) on Thursday reported a loss of $6 million in its third quarter.
RPTP: 9.34 (+0.56)

Raptor Pharmaceutical beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:29PM CST

RPTP: 9.34 (+0.56)

Raptor Pharmaceutical Reports Third Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Nov 06, 3:20PM CST
Global Net Product Sales for PROCYSBI of $23.8 Million for Third Quarter 2014
RPTP: 9.34 (+0.56)

Raptor Pharmaceutical to Hold Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, November 6, at 4:30 p.m. ET
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2014 financial results on Thursday, November 6, 2014 after market close. Management will conduct a conference call and live audio webcast at 4:30 p.m. ET (1:30 p.m. PT) that day to discuss the financial results and provide a corporate update.
RPTP: 9.34 (+0.56)

Raptor Pharmaceutical Announces Management Changes
GlobeNewswire - Thu Oct 23, 6:30AM CDT
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has strengthened its leadership team with the hiring of two new executives: David Happel, Chief Commercial Officer, who will oversee Raptor's global commercial operations, and Kimberly Lee, D.O., Vice President, Corporate Strategy and Communications, who will lead strategy development, investor relations and media communications.
RPTP: 9.34 (+0.56)

Today's Weak On High Volume Stock: Raptor Pharmaceutical (RPTP)
at The Street - Tue Oct 07, 9:00AM CDT
Trade-Ideas LLC identified Raptor Pharmaceutical (RPTP) as a weak on high relative volume candidate
RPTP: 9.34 (+0.56)

Raptor Pharmaceuticals (RPTP) Crumbles: Stock Falls by 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 7:36AM CDT
Raptor Pharmaceuticals (RPTP) fell over 7% in the last trading session amid huge volumes, continuing its recent trend, as the stock is now down over 11% since Sep 11.
CBM: 21.62 (+0.37), RPTP: 9.34 (+0.56), GILD: 91.29 (+1.84), PDLI: 7.61 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 72

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 81

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 65

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 15

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 71

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 34

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading

Top 5 Most Recently Viewed Articles

Carvana's Stock Peaks at $187.37 Amid Renewed Investor Confidence

Updated Category News Views 79

Carvana's Impressive Stock Surge to 52-Week High Recently, Carvana Co (NYSE: CVNA) achieved a remarkable milestone by hitting a 52-week high of $187.37. This surge highlights a robust recovery for the online used car retailer, whose stock has skyrocketed by an impressive 377.82% over the past year. This surge in stock price signifies renewed investor confidence in...

Continue Reading
ABM Industries Closes Q3 with Strong Earnings and Growth Boost

Updated Category News Views 133

ABM Industries Reports Strong Q3 Earnings ABM Industries (NYSE: ABM) saw its share price jump nearly 7% following the announcement of its third quarter earnings, which exceeded analyst expectations and prompted an upgrade to its full-year guidance. This positive outcome underscores the company's resilience in a challenging market landscape. Robust Financial Performance In...

Continue Reading
Transforming Senior Care: Click Holdings Embraces Cryptocurrency

Updated Category News Views 144

Innovative Strategies in Senior Care by Click Holdings Limited Click Holdings Limited (NASDAQ: CLIK) is making headlines with its groundbreaking approach to enhancing senior care services. Based in Hong Kong, this company combines cutting-edge human resources solutions with innovative cryptocurrency strategies, aiming to redefine how care services operate in an evolving...

Continue Reading
Cypress Creek and Meta Join Forces for Major Solar Project

Updated Category News Views 360

Cypress Creek and Meta's Renewable Energy Partnership In an exciting development, Cypress Creek Renewables and Meta have reached a significant milestone through their new Environmental Attribute Purchase Agreement (EAPA). This agreement is set to pave the way for the construction of a massive 505MWdc solar facility named Hanson Solar. With a capacity of 396MWac, this...

Continue Reading
The Shipyard Sets Sail with San Diego Headquarters Expansion

Updated Category News Views 462

The Shipyard Sets Sail with San Diego Headquarters Expansion The Shipyard, one of the fastest-growing independent marketing agencies in the nation, has announced an exciting development. The agency is expanding its operations by opening a new headquarters located in downtown San Diego at 185 West F Street. This move signifies a deepening of their commitment to California,...

Continue Reading